^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMF-001
i
Other names: IMF-001, IMF 001, CHP-NY-ESO-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ImmunoFrontier
Drug class:
Immunostimulant
Related drugs:
2years
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy. (PubMed, Cancer Immunol Immunother)
Fifty-four patients with NY-ESO-1-expressing ESCC who underwent radical surgery following cisplatin/5-fluorouracil-based neoadjuvant chemotherapy were assigned to receive either CHP-NY-ESO-1 vaccination or observation as control. These results suggest that PIGR would play a major role in tumor immunity in an antigen-specific manner during NY-ESO-1 vaccinations. The IgA response may be relevant.
Journal
|
CTAG1B (Cancer/testis antigen 1B)
|
CTAG1B expression
|
cisplatin • 5-fluorouracil • IMF-001
3years
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. (PubMed, Cancer Immunol Immunother)
In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule)
|
CTAG1B expression
|
Hiltonol (poly-ICLC) • IMF-001
Share via
